Paratek Pharmaceuticals, Inc.
PRTKNASDAQHealthcare
$2.23
+$0.04(+1.83%)
Market Cap$127828952
P/E Ratio—
52W High$3.65
52W Low$1.29
Paratek Pharmaceuticals, Inc. (PRTK) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRTK · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.06B) | ($0.06B) | ($0.10B) | ($0.13B) | ($0.11B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | ($0.00B) | ($0.00B) |
| Stock-Based Comp. | $0.01B | $0.01B | $0.01B | $0.01B | $0.03B |
| Change in Working Capital | ($0.02B) | ($0.01B) | ($0.02B) | ($0.02B) | $0.00B |
| Net Cash from Operations | ($0.07B) | ($0.05B) | ($0.10B) | ($0.13B) | ($0.08B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.02B) | ($0.02B) | ($0.03B) | ($0.10B) | ($0.29B) |
| Sales of Investments | $0.03B | $0.02B | $0.12B | $0.24B | $0.17B |
| Net Cash from Investing | $0.01B | $0.00B | $0.09B | $0.13B | ($0.13B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.01B | $0.02B | $0.01B | $0.06B | $0.22B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.07B) | ($0.05B) | ($0.10B) | ($0.13B) | ($0.08B) |
| FCF Margin %(computed) | -43.89% | -40.22% | -238.53% | -811.68% | -474.61% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Paratek Pharmaceuticals, Inc. data
About Paratek Pharmaceuticals, Inc. (PRTK) Cash Flow Statement
Paratek Pharmaceuticals, Inc. generated operating cash flow of ($0.07B) and free cash flow of ($0.07B) for 2022 — a FCF margin of -43.89%. Capital expenditure was ($0.00B).
Frequently asked questions
PRTK · 4 questionsParatek Pharmaceuticals, Inc. generated free cash flow of ($0.07B) for 2022, down 36.0% year-over-year.
PRTK free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10